PARP inhibitors and breast cancer: Update and perspectives;Inhibiteurs de la poly(ADP-ribose) polymerase et cancer du sein: Bilan et perspectives

Bulletin du Cancer

Volumn 99, Issue 4, 2012, Pages 441-451

  Gonçalves, Anthony ^a,b,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

BRCA1 2; Breast cancer; PARP; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

APOPTOSIS; DRUG EFFICACY; ENZYME INHIBITION; GENE TARGETING; HOMOLOGOUS RECOMBINATION; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIPLE NEGATIVE BREAST CANCER;

EID: 84860159513     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1553     Document Type: Article

References (57)

1. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 : 917-21. (Pubitemid 40559006)
2. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434 : 913-7. (Pubitemid 40559005)
3. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411 : 366-74. (Pubitemid 32467046)
4. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009; 361 : 1475-85.
5. Pourquier P, Robert J. General overview on DNA repair. Bull Cancer 2011; 98 : 229-37.
6. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26 : 882-93. (Pubitemid 39128102)
7. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011; 61 : 31-49.
8. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011; 22 : 268-79.
9. Dantzer F, Noel G, Schreiber V. PARP inhibitors: significant progress in cancer therapy. Bull Cancer 2011; 98 : 277-90.
10. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997; 94 : 7303-7. (Pubitemid 27345310)
11. Menissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003; 22 : 2255-63. (Pubitemid 36565548)
12. Patel KJ, Yu VP, Lee H, et al. Involvement of BRCA2 in DNA repair. Mol Cell 1998; 1 : 347-57. (Pubitemid 128378883)
13. Tutt A, Bertwistle D, Valentine J, et al. Mutation in BRCA2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20 : 4704-16. (Pubitemid 32848624)
14. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008; 39 : 857-65.
15. Wilson CA, Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999; 21 : 236-40. (Pubitemid 29070375)
16. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18 : 1957-65. (Pubitemid 29150082)
17. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92 : 564-9. (Pubitemid 30212318)
18. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4 : 814-9. (Pubitemid 39331153)
19. Hay T, Matthews JR, Pietzka L, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous BRCA2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69 : 3850-5.
20. Calvert H, Azzariti A. The clinical development of inhibitors of poly(ADP-ribose) polymerase. Ann Oncol 2011;22 (suppl. 1) : i53-9.
21. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105 : 17079-84.
22. Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14 : 3916-25.
23. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361 : 123-34.
24. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376 : 235-44.
25. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12 : 852-61.
26. Giaccone G, Rajan A, Kelly R, et al. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. J Clin Oncol 2010; 28 (abstract 3027).
27. Dent R, Lindeman G, Clemons M, et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010; 28 (abstract 1018).
28. Ossovskaya V, Lim Cu, Schools G, Kalurupalle S, Roninson IB, Broude E. Cell cycle effects of iniparib, a PARP inhibitor, in combination with gemcitabine and carboplatin in the MDA-MB-468(-) triple-negative breast cancer (TNBC) cell line. Cancer Res 2010 ; 70 (abstract P5-06-09).
29. Ossovskaya V, Lim CU, Schools G, Kalurupalle S, Roninson IB, Broude E. The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468(-) triple-negative breast cancer (TNBC) cell line. Cancer Res 2011 ; 71 : (abstract LB-401).
30. Kopetz S, Mita M, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol 2008; 26 (abstract 3577).
31. Mahany J, Lewis N, Heath E, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 2008; 26 (abstract 3579).
32. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triplenegative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009; 27 (abstract 3).
33. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364 : 205-14.
34. O'Shaughnessy J, Schwartzberg L, Danso MR, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29 (abstract 1007).
35. He JX, Yang CH, Miao ZH. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin 2010; 31 : 1172-80.
36. Maegley K, Bingham P, Tatlock J, Thomas H. All PARP inhibitors are not equal: an in vitro mechanistic comparison of PF-01367338 to iniparib. J Clin Oncol 2011 ; 29 (abstract e13576).
37. Ji J, Lee MP, Kadota M, et al. Pharmacodynamic and pathway analysis of three presumed inhibitors of poly(ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201. Cancer Res 2011; 71 (abstract 4527).
38. Isakoff S, Overmoyer B, Tung N, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010; 28(suppl.), 15s (abstract 1019).
39. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002; 94 : 990-1000. (Pubitemid 34814728)
40. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100 : 8418-23. (Pubitemid 36842560)
41. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344 : 539-48. (Pubitemid 32167867)
42. Hedenfalk IA. Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures. J Natl Cancer Inst 2002; 94 : 960-1. (Pubitemid 34814719)
43. Rodriguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010; 123 : 189-96.
44. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010; 28 : 3555-61.
45. van Beers EH, van Welsem T, Wessels LF, et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005; 65 : 822-7. (Pubitemid 40216440)
46. Joosse SA, van Beers EH, Tielen IH, et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array- CGH. Breast Cancer Res Treat 2009; 116 : 479-89.
47. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128 : 157-70. (Pubitemid 46048887)
48. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1 : 315-22.
49. Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009; 7 : 1304-9.
50. Asakawa H, Koizumi H, Koike A, et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 2010; 12 : R17.
51. Gonçalves A, Finetti P, Sabatier R, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat 2010; 127 : 273-81.
52. von Minckwitz G, Mãller BM, Loibl S, et al. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29 : 2150-7.
53. Gottipati P, Vischioni B, Schultz N, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010; 70 : 5389-98.
54. Yang SX, Kummar S, Steinberg SM, et al. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther 2009; 8 : 2004-9.
55. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451 : 1111-5. (Pubitemid 351317441)
56. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451 : 1116-20.
57. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68 : 2581-6.